FDA Brief

Warning letters Drugs

FDA warning letter to

Peak Performance Peptides

High riskIssued Aug 24Posted Sep 1Center for Drug Evaluation and Research (CDER)

Peak Performance Peptides sold unapproved injectable peptide drugs, including semaglutide and retatrutide, without FDA approval.

What happened

FDA reviewed the company's website, pppepz.com, in July 2026; no facility inspection was conducted. The agency found six products marketed with claims about treating disease and affecting body functions, which makes them drugs, and none has an FDA-approved application. FDA also noted the site sells "Bac water" as a solvent for reconstituting the peptides, which shows the products are meant for injection into people despite "research use only" statements.

What FDA found

  1. The company's website claims these peptides affect weight, blood sugar, hormones, and other body functions, which makes them drugs under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128
  2. The products are "new drugs" because they are not generally recognized as safe and effective for the uses in their labeling.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. The company sells these new drugs in interstate commerce without an FDA-approved application for any of them.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  4. "Bac water" is itself a drug because it is sold together with the peptides for reconstituting them for injection.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  5. Labels saying "research use only" and "not for human consumption" do not hold up, because the site makes drug claims and sells bacteriostatic water to prepare the products for injection.

What FDA wants

FDA tells the company to investigate the root causes, correct the violations, and explain in writing the steps taken to prevent them from happening again. The response must go to FDAAdvisory@fda.hhs.gov within 15 business days, with reference number 735127 in the subject line and copies of related documentation.

Who should pay attention

  • online sellers of peptides marketed for research use only
  • clinics and med spas that buy peptides from online suppliers
  • consumers buying injectable peptides directly from websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk